BioSpace News Archive

EAG Laboratories is pleased to announce the completed installation of a ThermoFisher Scientific Themis Z Transmission Electron Microscope (TEM) at our Silicon Valley facility. This next generation, ultra-high-resolution TEM is the first available in an independent laboratory in North America and is the second Themis Z owned by EAG Laboratories. The Themis Z is a monochromated, probe-corrected TEM operated in an e

Investment will enable Tremeau to advance the clinical development of TRM-201 (rofecoxib) Tremeau has gained agreement with FDA to initiate a pivotal Phase III trial for TRM-201 in hemophilic arthropathy (HA), a painful and debilitating joint disease If approved, TRM-201 would potentially be the first new oral non-opioid pain treatment in over 15 years, and the first specifically indicated for HA

Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced the launch of Galactosemia Together, the first and only industry-led Galactosemia awareness and education campaign.

Frazier Healthcare Partners’ special purpose acquisition corporation, Frazier Lifesciences Acquisition Corporation, announced the pricing of its initial public offering of 12,000,000 units, at a price to the public of $10.00 per unit, for aggregate gross proceeds of $120,000,000.

Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology and neuroscience, announced the presentation of new preclinical data on its VISTA antagonist antibodies at the European Society for Medical Oncology Virtual Congress 2020.

Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier Growth Market: ISOFOL) announces that 440 patients has been successfully recruited in the global Phase III AGENT study for the treatment for advanced colorectal cancer.

Mycovia Pharmaceuticals, Inc. (“Mycovia”), an emerging biopharmaceutical company dedicated to recognizing and empowering those living with unmet medical needs by developing novel therapies, today announced positive topline results from its two pivotal Phase 3 VIOLET clinical trials for oteseconazole, its drug candidate for treating patients with recurrent vulvovaginal candidiasis (RVVC).

Collaboration aims to accelerate the development and translation of Yale’s research and innovation projects to a decision point

Dyadic International, Inc. , a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products, at flexible commercial scales, today announced that its President and Chief Executive Officer, Mark Emalfarb, has confirmed an interview with FOX Business Network for the following program today:

Broad and deep portfolio of highly differentiated product candidates aligned with needs of patients and doctors Robust pipeline includes 4 development programs addressing 7 dermatological diseases, including 3 programs in Phase 2 or Phase 3 for 5 different indications Pipeline has potential to generate sales of ~$3 billion to $8 billion by 2030 in the U.S. market alone Live webcast and archived replay of Investor Day available in IR section of Arcutis website